Peter E. Westerweel

4.4k total citations
80 papers, 1.3k citations indexed

About

Peter E. Westerweel is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Peter E. Westerweel has authored 80 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 30 papers in Genetics and 19 papers in Oncology. Recurrent topics in Peter E. Westerweel's work include Chronic Myeloid Leukemia Treatments (32 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Angiogenesis and VEGF in Cancer (13 papers). Peter E. Westerweel is often cited by papers focused on Chronic Myeloid Leukemia Treatments (32 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Angiogenesis and VEGF in Cancer (13 papers). Peter E. Westerweel collaborates with scholars based in Netherlands, United States and Germany. Peter E. Westerweel's co-authors include Marianne C. Verhaar, Imo E. Hoefer, Hein A. Koomans, Mark‐David Levin, Jan J. Cornelissen, Clemens van Blitterswijk, Jeroen Rouwkema, Ronald H. W. M. Derksen, Jan de Boer and Jeroen J. W. M. Janssen and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Peter E. Westerweel

76 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter E. Westerweel Netherlands 20 402 323 289 199 191 80 1.3k
Laura Russo Italy 22 399 1.0× 464 1.4× 575 2.0× 213 1.1× 261 1.4× 56 1.7k
Roberto Castelli Italy 21 219 0.5× 670 2.1× 553 1.9× 164 0.8× 230 1.2× 86 1.6k
Jason Tay Canada 20 394 1.0× 321 1.0× 693 2.4× 219 1.1× 341 1.8× 108 1.6k
Marcel D. Posthumus Netherlands 20 285 0.7× 146 0.5× 215 0.7× 132 0.7× 149 0.8× 30 1.4k
Neta Goldschmidt Israel 23 268 0.7× 425 1.3× 355 1.2× 93 0.5× 331 1.7× 97 1.4k
Sergio Siragusa Italy 26 360 0.9× 470 1.5× 960 3.3× 360 1.8× 242 1.3× 150 2.1k
Jingyuan Xie China 21 318 0.8× 102 0.3× 194 0.7× 138 0.7× 128 0.7× 121 1.6k
Wenhui Xie China 22 215 0.5× 98 0.3× 127 0.4× 119 0.6× 233 1.2× 93 1.4k
Sébastien Viatte United Kingdom 19 307 0.8× 148 0.5× 250 0.9× 233 1.2× 161 0.8× 54 1.7k
Sung‐Hyun Kim South Korea 17 213 0.5× 171 0.5× 352 1.2× 136 0.7× 371 1.9× 105 1.0k

Countries citing papers authored by Peter E. Westerweel

Since Specialization
Citations

This map shows the geographic impact of Peter E. Westerweel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter E. Westerweel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter E. Westerweel more than expected).

Fields of papers citing papers by Peter E. Westerweel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter E. Westerweel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter E. Westerweel. The network helps show where Peter E. Westerweel may publish in the future.

Co-authorship network of co-authors of Peter E. Westerweel

This figure shows the co-authorship network connecting the top 25 collaborators of Peter E. Westerweel. A scholar is included among the top collaborators of Peter E. Westerweel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter E. Westerweel. Peter E. Westerweel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Netelenbos, Tanja, Marina Kartachova, Roger E. G. Schutgens, et al.. (2025). The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering. British Journal of Haematology. 206(6). 1743–1753.
2.
Kesteren, Charlotte van, et al.. (2024). Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series. Annals of Hematology. 103(11). 4765–4771. 4 indexed citations
3.
Lieshout, Rianne van, Lidwine W. Tick, Harry R. Koene, et al.. (2023). Medical nutrition therapy during intensive remission-induction treatment and hematopoietic stem cell transplantation in acute myeloid leukemia patients: Hematologists’ experiences and perspectives. Clinical Nutrition ESPEN. 57. 399–409. 1 indexed citations
4.
Ilander, Mette, Satu Mustjoki, Johan Richter, et al.. (2023). Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of Hematology. 102(6). 1395–1408. 5 indexed citations
5.
Dinmohamed, Avinash G., et al.. (2022). Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands. Leukemia & lymphoma. 64(2). 424–432. 1 indexed citations
6.
Hengeveld, Paul J., Frédéric Davi, François G. Kavelaars, et al.. (2022). Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL. Blood. 141(5). 519–528. 12 indexed citations
7.
Rier, Hánah N., Joost van Rosmalen, Peter E. Westerweel, et al.. (2022). Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with Cancer. The Oncologist. 27(11). e878–e888. 11 indexed citations
8.
Jong, Cindy M.M. de, Marc Blondon, Cihan Ay, et al.. (2022). Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism. Blood. 140(16). 1764–1773. 22 indexed citations
9.
Visser, Otto, Eduardus F. M. Posthuma, Peter E. Westerweel, et al.. (2021). Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands. Leukemia. 35(11). 3291–3294. 2 indexed citations
10.
Klaveren, David van, Eduardus F. M. Posthuma, Otto Visser, et al.. (2021). The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018. British Journal of Haematology. 196(5). 1219–1224. 14 indexed citations
11.
Westerweel, Peter E., et al.. (2020). The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach. Journal of Medical Internet Research. 22(5). e15895–e15895. 28 indexed citations
12.
13.
Hengeveld, Paul J., et al.. (2020). Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma. BMJ Case Reports. 13(7). e235216–e235216. 5 indexed citations
14.
Govers, Tim M., et al.. (2019). The potential health gain and cost savings of improving adherence in chronic myeloid leukemia. Leukemia & lymphoma. 60(6). 1485–1492. 4 indexed citations
15.
Saglio, Giuseppe, António Almeida, Andrija Bogdanović, et al.. (2018). Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective. Clinical Lymphoma Myeloma & Leukemia. 18(6). 375–379. 14 indexed citations
16.
Thielen, Noortje, Jeroen J. W. M. Janssen, Mels Hoogendoorn, et al.. (2017). Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe. European Journal Of Haematology. 100(4). 367–371. 3 indexed citations
17.
Hermens, Rosella, et al.. (2017). CMyLife: een eerste inzicht in kwaliteit van leven en verbetermogelijkheden bij CML-patiënten voorafgaand aan gebruik van CMyLife. Radboud Repository (Radboud University). 4. 183–189. 1 indexed citations
18.
Rouwkema, Jeroen, Peter E. Westerweel, Jan de Boer, Marianne C. Verhaar, & Clemens van Blitterswijk. (2009). The Use of Endothelial Progenitor Cells for Prevascularized Bone Tissue Engineering. Tissue Engineering Part A. 15(8). 2015–2027. 97 indexed citations
19.
Westerweel, Peter E. & Marianne C. Verhaar. (2009). Endothelial progenitor cell dysfunction in rheumatic disease. Nature Reviews Rheumatology. 5(6). 332–340. 44 indexed citations
20.
Westerweel, Peter E., et al.. (2007). Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis & Rheumatism. 56(5). 1384–1396. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Russo Breakdown of academic impact, for papers by Roberto Castelli Breakdown of academic impact, for papers by Jason Tay Breakdown of academic impact, for papers by Marcel D. Posthumus Breakdown of academic impact, for papers by Neta Goldschmidt Breakdown of academic impact, for papers by Sergio Siragusa Breakdown of academic impact, for papers by Jingyuan Xie Breakdown of academic impact, for papers by Wenhui Xie Breakdown of academic impact, for papers by Sébastien Viatte Breakdown of academic impact, for papers by Sung‐Hyun Kim
Rankless by CCL
2026